Nant cancer vaccine strategies

A method of treating a cancer patient having two anatomically distinct tumors, comprising:

• obtaining a first omics data set from a first tumor tissue of the patient and a second omics data set from a second tumor tissue derived from a bodily fluid sample of the patient wherein the first and second tumor tissues are anatomically distinct tumors;
• 1) determining a first tumor microenvironment status of the first tumor tissue based on the first omics data set and a second tumor microenvironment status of the second tumor tissue based on the second omics data set;
• wherein the tumor microenvironment status are selected from a group consisting of an escape phase, an elimination phase, and an equilibrium phase;
• 2) treating the patient with a treatment regimen that is determined based on the first and second phases of the first and second tumor tissues, respectively;
• and
• wherein the treatment regimen comprises at least one of a first pharmaceutical composition that reverts the escape phase by reducing immune suppression in a tumor microenvironment wherein the first pharmaceutical composition is selected from a group consisting of Bendamustine, Bortezomib, Cabazitaxel, Chlorambucil, Cisplatin, Cyclophosphamide, Dasatinib, Docetaxel, Doxorubicin, Epirubicin, Erlotinib, Etoposide, Everolimus, Gefitinib, Idarubicin, Hydroxyurea, Imatinib, Lapatinib, Melphalan, Mitoxantrone, Nilotinib, Oxiplatin, Paclitaxel, Pazopanib, Pemetrexed, Rapamycin, Romidepsin, Sorafenib, Vemurafenib, Sunitinib, Teniposide, Vinblastine, Vinorelbine, and Vincristine, abciximab, Trastuzumab emtansine, Alemtuzumab, Basiliximab, Bevacizumab, Belimumab, Brentuximab vedotin, Certolizumab pegol, Cetuximab, Denosumab, Ibritumomab tiuxetan, Natalizumab, Obinutuzumab, Ofatumumab, Omalizumab, Panitumumab, Pertuzumab, Ramucirumab, Ranibizumab, Rituximab, Tositumomab, Trabectedin, Trastuzumab, cisplatin, gemcitabine, 5-fluorouracil, cyclophosphamide, doxorubicin, temozolomide, docetaxel, paclitaxel, trabectedin, and RP-182,
• a second pharmaceutical composition that induces the elimination phase by enhancing at least one of an adaptive immune response and an innate immune response wherein the second pharmaceutical composition is selected from the group consisting of an aNK cell, a haNK cell, a taNK cell, IL-2, IL-15, IL-17, IL-21, and Alt-803, or
• a third pharmaceutical composition that maintains the equilibrium phase by biasing the adaptive immune response towards a TH1 response wherein the third pharmaceutical composition is a checkpoint inhibitor selected from the group consisting of a PD-1 inhibitor and a CTLA4 inhibitor, and/or an immune stimulatory cytokine selected from the group consisting of IL-2, IL-15, IL-17, IL-21, and Alt-803.